Quarterly report [Sections 13 or 15(d)]

Segment Information (Tables)

v3.25.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Reconciliation Of Operating Profit Loss From Segments To Consolidated For additional information on the year over year change of segment expenses refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

 

Three months ended March 31,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Research and development expenses:

 

 

 

 

 

 

Personnel

 

$

11,365

 

 

$

7,763

 

Clinical trials

 

 

8,511

 

 

 

4,421

 

Development services

 

 

3,567

 

 

 

4,347

 

Manufacturing of preclinical and clinical supplies

 

 

5,032

 

 

 

3,543

 

License of intellectual property

 

 

—

 

 

 

1,511

 

Other research and development costs (1)

 

 

543

 

 

 

369

 

General and administration expenses

 

 

8,118

 

 

 

6,077

 

Interest income

 

 

(1,487

)

 

 

(2,984

)

Interest expense

 

 

294

 

 

 

—

 

Net loss

 

$

35,943

 

 

$

25,047

 

(1) Other research and development costs includes costs associated with information technology, travel, medical and scientific symposiums and conferences.